Mannatech Inc

Mannatech Inc (MTEX) Stock Analysis

$7.180

+0.469 (+6.53%)At close

Loading chart…
High
7.180
Open
7.180
VWAP
7.09
Vol
3.03K
Mkt Cap
13.10M
Low
6.910
Amount
21.47K
EV/EBITDA, TTM
0.00

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies.

AI analysis of Mannatech Inc (MTEX)

buy

Mannatech Inc (MTEX) appears to be a good buy right now, primarily due to its recent upward momentum and improving financial metrics. The stock has seen a 5-day change of +6.65% and a significant increase of +40.71% over the past 20 days, indicating strong short-term performance. Additionally, the current RSI is at 61.75, suggesting that the stock is gaining momentum without being overbought. However, investors should be cautious of the net income trend, which has shown significant losses, with a recent EPS of -5.94 in Q4 2025 being a major risk factor.

Valuation Metrics

The current forward P/E ratio for Mannatech Inc (MTEX) is 9.57, compared to its 5-year average forward P/E of 1.29.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.29
Current P/E
9.57
Overvalued
4.41
Undervalued
-1.84

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for MTEX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MTEX

$9.48

Scenario price

B

Base

Base · 50%MTEX

$7.93

Scenario price

B

Bear

Bear · 25%MTEX

$7.87

Scenario price

Events Timeline

2026-08-14 (ET)

14:30:00

Mannatech Trading Resumes

14:30:00

Mannatech Trading Halted Due to Volatility

2026-04-07 (ET)

16:00:00

Mannatech Trading Halted Due to Volatility

2024-11-26 (ET)

15:30:47

Mannatech names Robert Toth vice chairman of the board

News

MTEX FAQ — answered by Alphio AI

Mannatech, Incorporated is a global health and wellness solution provider. The Company develops and sells nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness. The Company's product category includes Integrative Health, Targeted Health, Weight and Fitness, Skin Care, and Essentials. Integrative Health includes Ambrotose Complex, Ambrotose AO, Advanced Ambrotose, Ambrotose Life, Catalyst, Cognitate, Manapol Powder, MannaBears, and others. Targeted Health includes BounceBack, CardioBALANCE, GI-ProBalance Slimstick, GI-Zyme, GI-Defense, Blood Sugar ProBalance, ImmunoSTART, and others. Weight and Fitness includes OsoLean, SPORT, TruHealth Fat Loss System and others. Skin Care includes Emprizone, FIRM with Ambrotose, FreshDen, and others. Essentials include Catalyst Multivitamin, Liver Support, Joint Support SUPERFOOD, Sleep Support gummies and Stress Support gummies. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Mannatech Inc (MTEX) appears to be a good buy right now, primarily due to its recent upward momentum and improving financial metrics. The stock has seen a 5-day change of +6.65% and a significant increase of +40.71% over the past 20 days, indicating strong short-term performance. Additionally, the current RSI is at 61.75, suggesting that the stock is gaining momentum without being overbought. However, investors should be cautious of the net income trend, which has shown significant losses, with a recent EPS of -5.94 in Q4 2025 being a major risk factor.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started